Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials

Academic Emergency Medicine

Volumn 23, Issue 4, 2016, Pages 466-475

  Milling, Truman J ^a   Refaai, Majed A ^b   Sarode, Ravi ^c   Lewis, Brandon ^d   Mangione, Antoinette ^e   Durn, Billie L ^e   Harman, Amy ^e   Lee, Martin L ^f   Goldstein, Joshua N ^g  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^e CSL BEHRING   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; PHYTOMENADIONE; PROTEIN C; PROTHROMBIN; PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES; VITAMIN K GROUP;

ADULT; ADVERSE OUTCOME; ANTICOAGULANT THERAPY; BLEEDING; BODY WEIGHT; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DESCRIPTIVE RESEARCH; DRUG SAFETY; HEART FAILURE; HUMAN; HYPERVOLEMIA; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; LUNG EDEMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; FEMALE; HEMORRHAGE; MALE; MIDDLE AGED;

AGED; BLOOD COAGULATION FACTORS; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLASMA; THROMBOEMBOLISM; VITAMIN K;

EID: 84961721068     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/acem.12911     Document Type: Conference Paper

References (30)

1. IMS data US National Prescription Audit. Danbury, CT: IMS Health, 2013.
2. Budnitz DS, Lovegrove MC, Shehab N, Richards CL,. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-12.
3. Wysowski DK, Nourjah P, Swartz L,. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-9.
4. Ageno W, Gallus AS, Wittkowsky A, et al., Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e44S-88S.
5. Levy JH, Tanaka KA, Dietrich W,. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109: 918-26.
6. Holbrook A, Schulman S, Witt DM, et al., Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e152S-84S.
7. Keeling D, Baglin T, Tait C, et al., Guidelines on oral anticoagulation with warfarin-fourth edition. Br J Haematol 2011; 154: 311-24.
8. Spahn DR, Bouillon B, Cerny V, et al., Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17: R76.
9. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al., Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382.
10. Sarode R, Milling TJ Jr, Refaai MA, et al., Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128: 1234-43.
11. Goldstein JN, Refaai MA, Milling TJ Jr, et al., Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015; 385: 2077-87.
12. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G,. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 160S-98S.
13. Kcentra Highlights of Prescribing Information. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM350239.pdf. Accessed Oct 23, 2015.
14. Milling TJ Jr, Refaai MA, Goldstein JN, et al., Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med 2016; 67: 96-105.
15. Refaai MA, Goldstein JN, Lee ML, Durn BL, Milling TJ Jr, Sarode R,. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal. Transfusion 2015; 2722-9.
16. Demeyere R, Gillardin S, Arnout J, Strengers PF,. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010; 99: 251-60.
17. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H,. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6: 622-31.
18. Preston FE, Laidlaw ST, Sampson B, Kitchen S,. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002; 116: 619-24.
19. Lorenz R, Kienast J, Otto U, et al., Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study. Blood Coagul Fibrinolysis 2007; 18: 565-70.
20. Hanke AA, Joch C, Gorlinger K,. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. Br J Anaesth 2013; 110: 764-72.
21. Hickey M, Gatien M, Taljaard M, Aujnarain A, Giulivi A, Perry JJ,. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation 2013; 128: 360-4.
22. Lubetsky A, Hoffman R, Zimlichman R, et al., Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004; 113: 371-8.
23. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R,. Clinical review: prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care 2011; 15: 201.
24. Dentali F, Marchesi C, Pierfranceschi MG, et al., Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106: 429-38.
25. Prandoni P, Noventa F, Ghirarduzzi A, et al., The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199-205.
26. Witt DM, Delate T, Garcia DA, et al., Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 172: 1484-91.
27. Bolton-Maggs PH, Cohen H,. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013; 163: 303-14.
28. Pandey S, Vyas GN,. Adverse effects of plasma transfusion. Transfusion 2012; 52 (Suppl 1): 65S-79S.
29. Li G, Rachmale S, Kojicic M, et al., Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion 2011; 51: 338-43.
30. Magee G, Zbrozek A,. Fluid overload is associated with increases in length of stay and hospital costs: pooled analysis of data from more than 600 US hospitals. Clinicoecon Outcomes Res 2013; 5: 289-96.